FindTrial
Sign In

Tyrosine Kinase Inhibitor for the Treatment of Severe Pulmonary Arterial Hypertension

Tyrosine Kinase Inhibitor for the Treatment of Severe Pulmonary Arterial Hypertension - Tyrosine Kinase Inhibitor for Pulmonary Arterial Hypertension

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001578
Enrollment
10
Registered
2008-12-16
Start date
2008-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension

Interventions

administration of tyrosine kinase inhibitor (imatinib)

Sponsors

Medical Education Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with severe pulmonary arterial hypertension who are refractory for conventional therapies such as PGIS, Ca-blocker, bosentan, and sildenafil

Exclusion criteria

Exclusion criteria: patients who can not express subjective symptoms, can not be evaluated through objective improvement, have the decreased number of platelet (less than 30000), have critical anemia (Hb<7.0), have critical liver cirrhosis, are during pregnancy or during lactation, or have critical left heart disease

Design outcomes

Primary

MeasureTime frame
subjective symptom (WHO functional classification), 6 minutes walk test, echocardiography, right heart catheterization, serum BNP level—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026